{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:27:17Z","timestamp":1793831237410,"version":"4.6.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    While multiple pharmacological drugs have been associated with myocarditis, temporal trends and overall mortality have not been reported. Here we report the spectrum and main features of 5108 reports of drug-induced myocarditis, in a worldwide pharmacovigilance analysis, comprising more than 21 million individual-case-safety reports from 1967 to 2020. Significant association between myocarditis and a suspected drug is assessed using disproportionality analyses, which use Bayesian information component estimates. Overall, we identify 62 drugs associated with myocarditis, 41 of which are categorized into 5 main pharmacological classes: antipsychotics (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20093108 reports), salicylates (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009340), antineoplastic-cytotoxics (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009190), antineoplastic-immunotherapies (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009538), and vaccines (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009790). Thirty-eight (61.3%) drugs were not previously reported associated with myocarditis. Antipsychotic was the first (1979) and most reported class (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20093018). In 2019, the two most reported classes were antipsychotics (54.7%) and immunotherapies (29.5%). Time-to-onset between treatment start and myocarditis is 15 [interquartile range: 10; 23] days. Subsequent mortality is 10.3% and differs between drug classes with immunotherapies the highest, 32.5% and salicylates the lowest, 2.6%. These elements highlight the diversity of presentations of myocarditis depending on drug class, and show the emerging role of antineoplastic drugs in the field of drug-induced myocarditis.\n                  <\/jats:p>","DOI":"10.1038\/s41467-021-27631-8","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T06:03:42Z","timestamp":1641794622000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":128,"title":["Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6014-6269","authenticated-orcid":false,"given":"Lee S.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie T.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Kerneis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0406-5189","authenticated-orcid":false,"given":"Christian","family":"Funck-Brentano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanne","family":"Silvain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Brechot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Hekimian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Ammirati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badr","family":"Ben M\u2019Barek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alban","family":"Redheuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Gandjbakhch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6797-0237","authenticated-orcid":false,"given":"Kevin","family":"Bihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Lebrun-Vignes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Ederhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Dolladille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javid J.","family":"Moslehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0331-3307","authenticated-orcid":false,"given":"Joe-Elie","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"key":"27631_CR1","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1161\/CIR.0000000000000745","volume":"141","author":"RD Kociol","year":"2020","unstructured":"Kociol, R. D. et al. Recognition and initial management of fulminant myocarditis. Circulation 141, e69\u2013e92 (2020).","journal-title":"Circulation"},{"key":"27631_CR2","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1161\/CIRCULATIONAHA.118.035319","volume":"138","author":"E Ammirati","year":"2018","unstructured":"Ammirati, E. et al. Clinical presentation and outcome in a contemporary cohort of patients with acute myocarditis: multicenter Lombardy Registry. Circulation 138, 1088\u20131099 (2018).","journal-title":"Circulation"},{"key":"27631_CR3","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S0140-6736(15)60692-4","volume":"386","author":"T Vos","year":"2015","unstructured":"Vos, T. et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386, 743\u2013800 (2015).","journal-title":"Lancet"},{"key":"27631_CR4","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","volume":"392","author":"SL James","year":"2018","unstructured":"James, S. L. et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392, 1789\u20131858 (2018).","journal-title":"Lancet"},{"key":"27631_CR5","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson, D. B. et al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 375, 1749\u20131755 (2016).","journal-title":"N. Engl. J. Med."},{"key":"27631_CR6","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1016\/j.jacc.2017.09.023","volume":"70","author":"M Brambatti","year":"2017","unstructured":"Brambatti, M. et al. Eosinophilic myocarditis: characteristics, treatment, and outcomes. J. Am. Coll. Cardiol. 70, 2363\u20132375 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"27631_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19979-7","volume":"8","author":"C Xiao","year":"2018","unstructured":"Xiao, C., Li, Y., Baytas, I. M., Zhou, J. & Wang, F. An MCEM Framework for drug safety signal detection and combination from heterogeneous real world evidence. Sci. Rep. 8, 1806 (2018).","journal-title":"Sci. Rep."},{"key":"27631_CR8","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem, J. E. et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 19, 1579\u20131589 (2018).","journal-title":"Lancet Oncol."},{"key":"27631_CR9","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1016\/S0140-6736(99)10385-4","volume":"354","author":"JG Kilian","year":"1999","unstructured":"Kilian, J. G., Kerr, K., Lawrence, C. & Celermajer, D. S. Myocarditis and cardiomyopathy associated with clozapine. Lancet 354, 1841\u20131845 (1999).","journal-title":"Lancet"},{"key":"27631_CR10","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1136\/bmj.322.7296.1207","volume":"322","author":"DM Coulter","year":"2001","unstructured":"Coulter, D. M., Bate, A., Meyboom, R. H., Lindquist, M. & Edwards, I. R. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ 322, 1207\u20131209 (2001).","journal-title":"BMJ"},{"key":"27631_CR11","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1161\/CIRCRESAHA.117.310221","volume":"121","author":"BH Trachtenberg","year":"2017","unstructured":"Trachtenberg, B. H. & Hare, J. M. Inflammatory cardiomyopathic syndromes. Circulation Res. 121, 803\u2013818 (2017).","journal-title":"Circulation Res."},{"key":"27631_CR12","doi-asserted-by":"crossref","unstructured":"Kerneis, M. Bihan, K. & Salem, J. E. COVID-19 vaccines and myocarditis. Arch. Cardiovasc Dis. 114, 515\u2013517 (2021).","DOI":"10.1016\/j.acvd.2021.06.001"},{"key":"27631_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.therap.2016.02.010","volume":"71","author":"G Miremont-Salam\u00e9","year":"2016","unstructured":"Miremont-Salam\u00e9, G., Th\u00e9ophile, H., Haramburu, F. & B\u00e9gaud, B. Causality assessment in pharmacovigilance: the French method and its successive updates. Therapie 71, 179\u2013186 (2016).","journal-title":"Therapie"},{"key":"27631_CR14","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1161\/CIRCULATIONAHA.119.040162","volume":"140","author":"JE Salem","year":"2019","unstructured":"Salem, J. E. et al. Androgenic effects on ventricular repolarization: a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes. Circulation 140, 1070\u20131080 (2019).","journal-title":"Circulation"},{"key":"27631_CR15","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40264-016-0405-1","volume":"39","author":"AF Wisniewski","year":"2016","unstructured":"Wisniewski, A. F. et al. Good signal detection practices: evidence from IMI PROTECT. Drug Saf. 39, 469\u2013490 (2016).","journal-title":"Drug Saf."},{"key":"27631_CR16","doi-asserted-by":"crossref","unstructured":"Xiao, L. et. al. Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal src kinase. Circulation. 142, 2443\u20132455 (2020).","DOI":"10.1161\/CIRCULATIONAHA.120.049210"},{"key":"27631_CR17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ijcard.2017.12.102","volume":"259","author":"BL Bellissima","year":"2018","unstructured":"Bellissima, B. L., Tingle, M. D., Cicovic, A., Alawami, M. & Kenedi, C. A systematic review of clozapine-induced myocarditis. Int. J. Cardiol. 259, 122\u2013129 (2018).","journal-title":"Int. J. Cardiol."},{"key":"27631_CR18","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/00004714-200108000-00005","volume":"21","author":"S H\u00e4gg","year":"2001","unstructured":"H\u00e4gg, S., Spigset, O., Bate, A. & Soderstr\u00f6m, T. G. Myocarditis related to clozapine treatment. J. Clin. Psychopharmacol. 21, 382\u2013388 (2001).","journal-title":"J. Clin. Psychopharmacol."},{"key":"27631_CR19","first-page":"466","volume":"69","author":"G Brown","year":"2016","unstructured":"Brown, G. 5-aminosalicylic acid-associated myocarditis and pericarditis: a narrative review. Can. J. Hospital Pharm. 69, 466\u2013472 (2016).","journal-title":"Can. J. Hospital Pharm."},{"key":"27631_CR20","doi-asserted-by":"publisher","first-page":"E46","DOI":"10.1002\/ibd.22985","volume":"19","author":"T Sabatini","year":"2013","unstructured":"Sabatini, T., Filippini, A., Nicosia, F., Preti, S. & Bertoli, M. Recurrence of myocarditis after mesalazine treatment for ulcerative colitis: a case report. Inflamm. Bowel Dis. 19, E46\u2013E48 (2013).","journal-title":"Inflamm. Bowel Dis."},{"key":"27631_CR21","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMc1901677","volume":"380","author":"J.E. Salem","year":"2019","unstructured":"Salem, J. E. et al. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N. Engl. J. Med. 380, 2377\u20132379 (2019).","journal-title":"N. Engl. J. Med."},{"key":"27631_CR22","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","volume":"140","author":"MP Bonaca","year":"2019","unstructured":"Bonaca, M. P. et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation 140, 80\u201391 (2019).","journal-title":"Circulation"},{"key":"27631_CR23","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/17843286.1999.11754231","volume":"54","author":"S Tas","year":"1999","unstructured":"Tas, S. & Simonart, T. Drug rash with eosinophilia and systemic symptoms (DRESS syndrome). Acta Clin. Belgica 54, 197\u2013200 (1999).","journal-title":"Acta Clin. Belgica"},{"key":"27631_CR24","doi-asserted-by":"crossref","unstructured":"Citrome, L., McEvoy, J. P., & Saklad, S. R. Guide to the management of clozapine-related tolerability and safety concerns. Clin. Schizophr. Relat. Psychoses. 10, 163\u2013177 (2016).","DOI":"10.3371\/1935-1232.10.3.163"},{"key":"27631_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejphar.2008.06.088","volume":"592","author":"JF Wang","year":"2008","unstructured":"Wang, J. F. et al. Clozapine-induced myocarditis: role of catecholamines in a murine model. Eur. J. Pharmacol. 592, 123\u2013127 (2008).","journal-title":"Eur. J. Pharmacol."},{"key":"27631_CR26","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/00005176-199710000-00015","volume":"25","author":"GC Kaiser","year":"1997","unstructured":"Kaiser, G. C., Milov, D. E., Erhart, N. A. & Bailey, D. J. Massive pericardial effusion in a child following the administration of mesalamine. J. Pediatr. Gastroenterol. Nutr. 25, 435\u2013438 (1997).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"27631_CR27","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/cvr\/cvz026","volume":"115","author":"JR Hu","year":"2019","unstructured":"Hu, J. R. et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc. Res. 115, 854\u2013868 (2019).","journal-title":"Cardiovasc. Res."},{"key":"27631_CR28","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/jnci\/djp440","volume":"102","author":"A Albini","year":"2010","unstructured":"Albini, A. et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J. Natl Cancer Inst. 102, 14\u201325 (2010).","journal-title":"J. Natl Cancer Inst."},{"key":"27631_CR29","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.jacc.2003.11.053","volume":"43","author":"DC Cassimatis","year":"2004","unstructured":"Cassimatis, D. C. et al. Smallpox vaccination and myopericarditis: a clinical review. J. Am. Coll. Cardiol. 43, 1503\u20131510 (2004).","journal-title":"J. Am. Coll. Cardiol."},{"key":"27631_CR30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41569-020-00435-x","volume":"18","author":"C Tsch\u00f6pe","year":"2021","unstructured":"Tsch\u00f6pe, C. et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat. Rev. Cardiol. 18, 169\u2013193 (2021).","journal-title":"Nat. Rev. Cardiol."},{"key":"27631_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6804a1","volume":"68","author":"WA Bower","year":"2019","unstructured":"Bower, W. A. et al. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices, 2019. MMWR Recomm. Rep. 68, 1\u201314 (2019).","journal-title":"MMWR Recomm. Rep."},{"key":"27631_CR32","doi-asserted-by":"publisher","first-page":"857","DOI":"10.2165\/00002018-200427120-00003","volume":"27","author":"M Lindquist","year":"2004","unstructured":"Lindquist, M. Data quality management in pharmacovigilance. Drug Saf. 27, 857\u2013870 (2004).","journal-title":"Drug Saf."},{"key":"27631_CR33","unstructured":"International Council for Harmonization. Introductory Guide to MedDRA. Accessible at: https:\/\/www.meddra.org\/how-to-use\/support-documentation\/english."},{"key":"27631_CR34","unstructured":"Food and Drug Administration. FDA Online Label Repository. Accessible at: https:\/\/labels.fda.gov\/proprietaryname.cfm."},{"key":"27631_CR35","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1093\/eurheartj\/eht210","volume":"34","author":"ALP Caforio","year":"2013","unstructured":"Caforio, A. L. P. et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 34, 2636\u20132648 (2013).","journal-title":"Eur. Heart J."},{"key":"27631_CR36","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate, A. et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. 54, 315\u2013321 (1998).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"27631_CR37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Nor\u00e9n","year":"2013","unstructured":"Nor\u00e9n, G. N., Hopstadius, J. & Bate, A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat. Methods Med. Res. 22, 57\u201369 (2013).","journal-title":"Stat. Methods Med. Res."},{"key":"27631_CR38","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","volume":"74","author":"JE Salem","year":"2019","unstructured":"Salem, J. E. et al. Cardiovascular toxicities associated with ibrutinib. J. Am. Coll. Cardiol. 74, 1667\u20131678 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"27631_CR39","doi-asserted-by":"crossref","unstructured":"Salem, J. E., et al. Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study. Eur. Heart J. 42, 3915\u20133928 (2021).","DOI":"10.1093\/eurheartj\/ehab362"},{"key":"27631_CR40","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1161\/CIRCULATIONAHA.120.048238","volume":"142","author":"LS Nguyen","year":"2020","unstructured":"Nguyen, L. S. et al. Cardiovascular toxicities associated with hydroxychloroquine and azithromycin: an analysis of the World Health Organization Pharmacovigilance Database. Circulation 142, 303\u2013305 (2020).","journal-title":"Circulation"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27631-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27631-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27631-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T10:32:00Z","timestamp":1669285920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27631-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,10]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["27631"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-27631-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,10]]},"assertion":[{"value":"11 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.K. has received consulting fees from Sanofi, lecture fees from Bayer, a research grant from PHRC 2015 (P150921), Federation Fran\u00e7aise de Cardiologie. J.S. reports during the past 2 years the following disclosures: consulting Fees or Lecture Fees or Travel Support from AstraZeneca, Bayer HealthCare SAS, Boehringer Ingelheim France, CSL Behring SA, Gilead Science, Sanofi-Aventis France, Terumo France SAS, Abbott Medical France SAS, Stockholder of Pharmaseeds. B.B.M. has no conflict of interest regarding this work, and is currently employed by Kayrros (Paris, France). E. G. received consulting fees from consulting fees from Boston Scientific, Microport and Medtronic. J.J.M. received fees from Pfizer, Novartis, Bristol-Myers Squibb, Deciphera, Audentes Pharmaceuticals, Nektar, Takeda, Ipsen, Myokardia, AstraZeneca, GlaxoSmithKline, Intrexon, and Regeneron, and is supported by R01 HL141466. J.-E. S. has participated to BMS advisory boards. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The lead author (the manuscript\u2019s guarantor) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Transparency declaration"}}],"article-number":"25"}}